Inside a Stem Cell Trial

The Scientist takes us inside one of a number of trials of first generation autologous stem cell therapy aimed at regenerating the damage of heart disease: "More than 10 years ago, researchers isolated endothelial progenitor cells from the ranks of CD34+ cells derived from bone marrow or mobilized to the peripheral blood. This provided a rationale for the idea that CD34+ cells could induce angiogenesis. Human CD34+ cells have been shown to induce angiogenesis and improve cardiac function in a rat model of myocardial ischemia, and CD31+ cells, the pig analog of CD34+ cells, have been shown to do the same in that species. The Phase II trial Bergman is enrolled in follows a successful Phase I trial of the method in humans, using direct injection following catheterization because it can precisely target areas of ischemia."

Link: http://www.the-scientist.com/article/home/24908/

Comment Submission

Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.